Eligibility Criteria

Inclusion Criteria:

- Understand and voluntarily sign an informed consent form.

- Age =18 years at the time of signing the informed consent form.

- Able to adhere to the study visit schedule and other protocol requirements.

- Relapsed / Refractory Multiple Myeloma following at least two prior standard
therapies including lenalidomide. Induction therapy followed by autologous stem
cell transplantation (ASCT) is considered one regimen.

- Patients must be refractory to prior lenalidomide therapy. For the purpose of this
protocol, refractory will be defined as history of progression on a regimen
containing full or maximally tolerated dose of lenalidomide administered for a
minimum of at least one complete cycle of therapy.

- All patients must have measurable disease defined as one or more of the following
criteria:

- Serum monoclonal protein greater than 10 g/L, serum immunoglobulin free light
chain (FLC) more than 10 mg/dL and an abnormal FLC ratio, urine light-chain
excretion > 200 mg/24 h, measurable soft tissue plasmacytoma that has not been
irradiated, or greater than 30% plasma cells in bone marrow.

- All previous cancer therapy, including radiation, hormonal therapy and surgery, must
have been discontinued at least 2 weeks prior to treatment in this study.

- ECOG performance status of = 2 at study entry (see Appendix D).

- Laboratory test results within these ranges:

- Absolute neutrophil count = 1.0 x 1000/uL

- Platelet count = 75 x 1000/uL

- Serum creatinine = 2.5 mg/dL

- Total bilirubin = 2 mg/dL

- AST (SGOT) and ALT (SGPT) = 5 x ULN

- Disease free of prior malignancies for = 5 years with exception of currently treated
basal cell, squamous cell carcinoma of the skin, or carcinoma "insitu" of the cervix
or breast.

- Females of childbearing potential (FCBP)† must have a negative serum or urine
pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to
and again within 24 hours of starting pomalidomide and must either commit to
continued abstinence from heterosexual intercourse or begin TWO acceptable methods of
birth control, one highly effective method and one additional effective method AT THE
SAME TIME, at least 28 days before she starts taking pomalidomide. FCBP must also
agree to ongoing pregnancy testing. Men must agree to use a latex condom during
sexual contact with a FCBP even if they have had a vasectomy. All patients must be
counseled at a minimum of every 28 days about pregnancy precautions and risks of
fetal exposure. See Appendix A and B: Risks of Fetal Exposure, Pregnancy Testing
Guidelines and Acceptable Birth Control Methods, AND also Education and Counseling
Guidance Document.

- Able to take aspirin (81 mg) daily as prophylactic anticoagulation (patients
intolerant to ASA may use warfarin or low molecular weight heparin).

Exclusion Criteria:

- Any serious medical condition, laboratory abnormality, or psychiatric illness that
would prevent the subject from signing the informed consent form.

- Pregnant or breast feeding females. (Lactating females must agree not to breast feed
while taking pomalidomide).

- Women of child-bearing potential who are unwilling to use a dual method of
contraception; and men who are unwilling to use a condom.

- Any condition, including the presence of laboratory abnormalities, which places the
subject at unacceptable risk if he/she were to participate in the study or confounds
the ability to interpret data from the study.

- Use of any other experimental drug or therapy within 28 days of baseline.

- Known hypersensitivity to thalidomide or lenalidomide.

- The development of erythema nodosum if characterized by a desquamating rash while
taking thalidomide, pomalidomide or similar drugs.

- Any prior use of pomalidomide.

- Concurrent use of other anti-cancer agents or treatments.

- Known positive for HIV or active infectious hepatitis, B or C.

- Grade 3 or 4 peripheral neuropathy